Hypera S.A. (OTCMKTS:HYPMY) Short Interest Update

Hypera S.A. (OTCMKTS:HYPMY - Get Free Report) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 100 shares, a decrease of 98.3% from the March 31st total of 5,800 shares. Based on an average daily trading volume, of 8,500 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the company's stock are short sold.

Hypera Stock Down 7.3 %

Shares of OTCMKTS HYPMY traded down $0.29 during mid-day trading on Thursday, reaching $3.71. 11,122 shares of the company were exchanged, compared to its average volume of 8,280. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.68. The stock has a market cap of $2.35 billion, a price-to-earnings ratio of 15.46 and a beta of 0.75. Hypera has a 1 year low of $2.64 and a 1 year high of $6.02. The firm has a 50-day moving average of $3.46 and a 200 day moving average of $3.44.

Hypera (OTCMKTS:HYPMY - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The company reported ($0.04) earnings per share for the quarter. The company had revenue of $184.34 million for the quarter. Hypera had a return on equity of 13.18% and a net margin of 20.04%.

About Hypera

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.